Venous thromboembolism in multiple myeloma

Seminars in Thrombosis and Hemostasis

Volumn 40, Issue 3, 2014, Pages 338-347

  De Stefano, Valerio ^a   Za, Tommaso ^a   Rossi, Elena ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

antithrombotic prophylaxis; lenalidomide; multiple myeloma; thalidomide; venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ANTIANEMIC AGENT; ANTIINFECTIVE AGENT; BLOOD CLOTTING FACTOR 8; DEXAMETHASONE; DOXORUBICIN; FIBRINOGEN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PREDNISONE; PROTEIN S; THALIDOMIDE; VON WILLEBRAND FACTOR; WARFARIN;

AGING; ARTICLE; BLOOD LEVEL; BLOOD VISCOSITY; CENTRAL VENOUS CATHETER; DISEASE ASSOCIATION; DRUG THERAPY; HUMAN; HYPERCOAGULABILITY; INCIDENCE; KIDNEY DYSFUNCTION; MONOCLONAL IMMUNOGLOBULINEMIA; MONOTHERAPY; MULTIPLE MYELOMA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTOPENIA; THROMBOPHILIA; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; BLOOD; COMPLICATION; PATHOLOGY;

HUMANS; MULTIPLE MYELOMA; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84897954144     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1370793     Document Type: Article

References (100)

1. Cushman M., Tsai A. W., White R. H., et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med: 2004; 117 1 19 25
2. Nordström M., Lindblad B., Bergqvist D., Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med: 1992; 232 2 155 160
3. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost: 2000; 83 5 657 660
4. Naess I. A., Christiansen S. C., Romundstad P., Cannegieter S. C., Rosendaal F. R., Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost: 2007; 5 4 692 699
5. Heit J. A., Silverstein M. D., Mohr D. N., Petterson T. M., O'Fallon W. M., Melton L. J. III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med: 2000; 160 6 809 815
6. Samama M. M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med: 2000; 160 22 3415 3420
7. Ocak G., Vossen C. Y., Verduijn M., et al. Risk of venous thrombosis in patients with major illnesses: results from the MEGA study. J Thromb Haemost: 2013; 11 1 116 123
8. Blom J. W., Doggen C. J., Osanto S., Rosendaal F. R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA: 2005; 293 6 715 722
9. Ferlay J., Shin H. R., Bray F., Forman D., Mathers C., Parkin D. M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer: 2010; 127 12 2893 2917
10. Surveillance Epidemiology and End Results SEER 2006-2010. Available at: http://www.seer.cancer.gov/statfacts/html/mulmy.htlm. Accessed October 9, 2013
11. Kristinsson S. Y., Fears T. R., Gridley G., et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood: 2008; 112 9 3582 3586
12. Kristinsson S. Y., Pfeiffer R. M., Björkholm M., et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood: 2010; 115 24 4991 4998
13. Blom J. W., Vanderschoot J. P., Oostindiër M. J., Osanto S., van der Meer F. J., Rosendaal F. R. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost: 2006; 4 3 529 535
14. Cronin-Fenton D. P., Sondergaard F., Pedersen L. A., et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer: 2010; 103 7 947 953
15. Talamo G. P., Ibrahim S., Claxton D., Tricot G. J., Fink L. M., Zangari M. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. Blood Coagul Fibrinolysis: 2009; 20 5 337 339
16. Cini M., Zamagni E., Valdré L., et al. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. Eur J Haematol: 2010; 84 6 484 492
17. De Stefano V., Rossi E., Paciaroni K., Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica: 2002; 87 10 1095 1108
18. Elice F., Fink L., Tricot G., Barlogie B., Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol: 2006; 134 4 399 405
19. Sallah S., Husain A., Wan J., Vos P., Nguyen N. P. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol: 2004; 15 10 1490 1494
20. Srkalovic G., Cameron M. G., Rybicki L., Deitcher S. R., Kattke-Marchant K., Hussein M. A. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer: 2004; 101 3 558 566
21. Muslimani A. A., Spiro T. P., Chaudhry A. A., Taylor H. C., Jaiyesimi I., Daw H. A. Venous thromboembolism in patients with monoclonal gammopathy of undetermined significance. Clin Adv Hematol Oncol: 2009; 7 12 827 832
22. Hansson P. O., Welin L., Tibblin G., Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population. 'The Study of Men Born in 1913'. Arch Intern Med: 1997; 157 15 1665 1670
23. Cohen A. L., Sarid R. The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease. Thromb Res: 2010; 125 3 216 219
24. Gregersen H., Norgaard M., Severinsen M. T., Engebjerg M. C., Jensen P., Sorensen H. T. Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism. Eur J Haematol: 2011; 86 2 129 134
25. Za T., De Stefano V., Rossi E., et al. Multiple Myeloma GIMEMA-Latium Region Working Group. Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients. Br J Haematol: 2013; 160 5 673 679
26. Uaprasert N., Voorhees P. M., Mackman N., Key N. S. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis. Eur J Cancer: 2010; 46 10 1790 1799
27. Mehta J., Singhal S. Hyperviscosity syndrome in plasma cell dyscrasias. Semin Thromb Hemost: 2003; 29 5 467 471
28. Kwaan H. C. Hyperviscosity in plasma cell dyscrasias. Clin Hemorheol Microcirc: 2013; 55 1 75 83
29. Gabriel D. A., Smith L. A., Folds J. D., Davis L., Cancelosi S. E. The influence of immunoglobulin (IgG) on the assembly of fibrin gels. J Lab Clin Med: 1983; 101 4 545 552
30. Carr M. E. Jr, Zekert S. L. Abnormal clot retraction, altered fibrin structure, and normal platelet function in multiple myeloma. Am J Physiol: 1994; 266 3 Pt 2 H1195 H1201
31. Carr M. E. Jr, Dent R. M., Carr S. L. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. J Lab Clin Med: 1996; 128 1 83 88
32. Weisel J. W., Litvinov R. I. The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate. Cardiovasc Hematol Agents Med Chem: 2008; 6 3 161 180
33. Eby C. Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol: 2009; 145 2 151 163
34. Federici A. B., Rand J. H., Bucciarelli P., et al. Subcommittee on von Willebrand Factor. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost: 2000; 84 2 345 349
35. Yasin Z., Quick D., Thiagarajan P., Spoor D., Caraveo J., Palascak J. Light-chain paraproteins with lupus anticoagulant activity. Am J Hematol: 1999; 62 2 99 102
36. Gruber A., Blaskó G., Sas G. Functional deficiency of protein C and skin necrosis in multiple myeloma. Thromb Res: 1986; 42 4 579 581
37. Deitcher S. R., Erban J. K., Limentani S. A. Acquired free protein S deficiency associated with multiple myeloma: a case report. Am J Hematol: 1996; 51 4 319 323
38. Zamagni E., Brioli A., Tacchetti P., Zannetti B., Pantani L., Cavo M. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. Semin Thromb Hemost: 2011; 37 3 209 219
39. Mahindra A., Hideshima T., Anderson K. C. Multiple myeloma: biology of the disease. Blood Rev: 2010; 24 01 S5 S11
40. Kerr R., Stirling D., Ludlam C. A. Interleukin 6 and haemostasis. Br J Haematol: 2001; 115 1 3 12
41. Joseph L., Fink L. M., Hauer-Jensen M. Cytokines in coagulation and thrombosis: a preclinical and clinical review. Blood Coagul Fibrinolysis: 2002; 13 2 105 116
42. Gomperts E. D., Shulman G., Lynch S. R. Factor VIII and factor-VIII-related antigen in multiple myelomatosis and related conditions. Br J Haematol: 1976; 32 2 249 255
43. Leone G., Valori V. M., Zini G., Bavaro P., Bartoloni C., Bizzi B. Factor VIII complex in myelomatosis and related disorders. Ric Clin Lab: 1982; 12 4 581 588
44. Petropoulou A. D., Gerotziafas G. T., Samama M. M., Hatmi M., Rendu F., Elalamy I. In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide. Thromb Res: 2008; 121 4 493 497
45. van Marion A. M., Auwerda J. J., Lisman T., et al. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leuk Res: 2008; 32 7 1078 1084
46. Auwerda J. J., Sonneveld P., de Maat M. P., Leebeek F. W. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica: 2007; 92 2 279 280
47. Negaard H. F., Iversen P. O., Ostenstad B., Iversen N., Holme P. A., Sandset P. M. Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor. Thromb Haemost: 2008; 99 6 1040 1048
48. Auwerda J. J., Yuana Y., Osanto S., et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost: 2011; 105 1 14 20
49. Minnema M. C., Fijnheer R., De Groot P. G., Lokhorst H. M. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost: 2003; 1 3 445 449
50. Libourel E. J., Sonneveld P., van der Holt B., de Maat M. P., Leebeek F. W. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood: 2010; 116 1 22 26
51. Zangari M., Saghafifar F., Anaissie E., et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis: 2002; 13 3 187 192
52. Deitcher S. R., Choueiri T., Srkalovic G., Hussein M. A. Acquired activated protein C resistance in myeloma patients with venous thromboembolic events. Br J Haematol: 2003; 123 5 959
53. Zangari M., Berno T., Zhan F., Boucher K. M., Tricot G., Fink L. Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls. Blood Coagul Fibrinolysis: 2011; 22 5 420 423
54. Yaǧci M., Sucak G. T., Haznedar R. Fibrinolytic activity in multiple myeloma. Am J Hematol: 2003; 74 4 231 237
55. van Marion A. M., Auwerda J. J., Minnema M. C., et al. Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thromb Haemost: 2005; 94 6 1341 1343
56. Cortelezzi A., Moia M., Falanga A., et al. CATHEM Study Group. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol: 2005; 129 6 811 817
57. Kumar S. K., Dispenzieri A., Lacy M. Q., et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia: 2013; (e-pub ahead of print). doi:10.1038/leu.2013.313
58. Barlogie B., Jagannath S., Desikan K. R., et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood: 1999; 93 1 55 65
59. Musallam K. M., Dahdaleh F. S., Shamseddine A. I., Taher A. T. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thromb Res: 2009; 123 5 679 686
60. Bennett C. L., Angelotta C., Yarnold P. R., et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA: 2006; 296 21 2558 2560
61. Rajkumar S. V., Blood E., Vesole D., Fonseca R., Greipp P. R.; Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol: 2006; 24 3 431 436
62. Carrier M., Le Gal G., Tay J., Wu C., Lee A. Y. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost: 2011; 9 4 653 663
63. Zangari M., Anaissie E., Barlogie B., et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood: 2001; 98 5 1614 1615
64. Zangari M., Siegel E., Barlogie B., et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood: 2002; 100 4 1168 1171
65. Palumbo A., Bringhen S., Caravita T., et al. Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet: 2006; 367 9513 825 831
66. Hicks L. K., Haynes A. E., Reece D. E., et al. Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-based Care. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev: 2008; 34 5 442 452
67. Rajkumar S. V., Jacobus S., Callander N. S., et al. Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol: 2010; 11 1 29 37
68. Zonder J. A., Crowley J., Hussein M. A., et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood: 2010; 116 26 5838 5841
69. Attal M., Lauwers-Cances V., Marit G., et al. IFM Investigators. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med: 2012; 366 19 1782 1791
70. Fouquet G., Tardy S., Demarquette H., et al. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma. Cancer: 2013; 119 20 3680 3686
71. Knop S., Gerecke C., Liebisch P., et al. Lenalidomide, Adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood: 2009; 113 18 4137 4143
72. Palumbo A., Hajek R., Delforge M., et al. MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med: 2012; 366 19 1759 1769
73. Schey S. A., Fields P., Bartlett J. B., et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol: 2004; 22 16 3269 3276
74. Streetly M. J., Gyertson K., Daniel Y., Zeldis J. B., Kazmi M., Schey S. A. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol: 2008; 141 1 41 51
75. Lacy M. Q., Hayman S. R., Gertz M. A., et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia: 2010; 24 11 1934 1939
76. Lacy M. Q., Allred J. B., Gertz M. A., et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood: 2011; 118 11 2970 2975
77. Richardson P. G., Siegel D., Baz R., et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood: 2013; 121 11 1961 1967
78. Miguel J. S., Weisel K., Moreau P., et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol: 2013; 14 11 1055 1066
79. Zangari M., Fink L., Zhan F., Tricot G. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. Clin Lymphoma Myeloma Leuk: 2011; 11 2 228 236
80. Lonial S., Richardson P. G., San Miguel J., et al. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol: 2008; 143 2 222 229
81. Fusté B., Serradell M., Escolar G., et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost: 2002; 88 4 678 685
82. Tobu M., Iqbal O., Fareed D., et al. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Clin Appl Thromb Hemost: 2004; 10 3 225 232
83. Knight R., DeLap R. J., Zeldis J. B. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med: 2006; 354 19 2079 2080
84. Galli M., Elice F., Crippa C., Comotti B., Rodeghiero F., Barbui T. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. Haematologica: 2004; 89 9 1141 1142
85. Anaissie E. J., Coleman E. A., Goodwin J. A., et al. Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis. Cancer: 2012; 118 2 549 557
86. Leleu X., Rodon P., Hulin C., et al. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. Thromb Haemost: 2013; 110 4 844 851
87. Cavo M., Zamagni E., Tosi P., et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica: 2004; 89 7 826 831
88. Zangari M., Barlogie B., Anaissie E., et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol: 2004; 126 5 715 721
89. Minnema M. C., Breitkreutz I., Auwerda J. J., et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia: 2004; 18 12 2044 2046
90. Klein U., Kosely F., Hillengass J., et al. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol: 2009; 88 1 67 71
91. Baz R., Li L., Kottke-Marchant K., et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc: 2005; 80 12 1568 1574
92. Palumbo A., Rus C., Zeldis J. B., Rodeghiero F., Boccadoro M.; Italian Multiple Myeloma Network, Gimema. Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J Thromb Haemost: 2006; 4 8 1842 1845
93. Dunkley S., Gaudry L. Thalidomide causes platelet activation, which can be abrogated by aspirin. J Thromb Haemost: 2007; 5 6 1323 1325
94. Robak M., Treliński J., Chojnowski K. Hemostatic changes after 1.  month of thalidomide and dexamethasone therapy in patients with multiple myeloma. Med Oncol: 2012; 29 5 3574 3580
95. Abdullah W. Z., Roshan T. M., Hussin A., Zain W. S., Abdullah D. Increased PAC-1 expression among patients with multiple myeloma on concurrent thalidomide and warfarin. Blood Coagul Fibrinolysis: 2013; 24 8 893 895
96. Palumbo A., Cavo M., Bringhen S., et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol: 2011; 29 8 986 993
97. Larocca A., Cavallo F., Bringhen S., et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood: 2012; 119 4 933 939, quiz 1093
98. Palumbo A., Rajkumar S. V., Dimopoulos M. A., et al. International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia: 2008; 22 2 414 423
99. Kristinsson S. Y. Thrombosis in multiple myeloma. Hematology (Am Soc Hematol Educ Program): 2010; 2010 437 444
100. Lee A. Y., Peterson E. A. Treatment of cancer-associated thrombosis. Blood: 2013; 122 14 2310 2317